Jan 16th, 2017: New data published in Blood confirms that the chemo-protective effect of Myelo001 is specific to healthy tissue.
Apr 7th, 2016: First patient treated in MyeloConcept Phase IIa study of Myelo001 in Chemotherapy-Induced Neutropenia.
Feb 26th, 2016: Start of MyeloConcept Phase IIa study of Myelo001 in Chemotherapy-Induced Neutropenia.
June 27th, 2015: "Myelo001 – A Novel Small Molecule for the Treatment of Chemotherapy-Induced Myelosuppression" was presented at the MASCC/ISOO 2015 Annual Meeting on Supportive Care in Cancer.
Oct 6th, 2014: "Effect of Myelo001, a Novel Orally Bioavailable Small Molecule, on Chemotherapy-induced Myelosuppression" was accepted for poster presentation and publication at the 56th meeting of the American Society of Hematology, on Monday, Dec 8th, 2014 from 6:00 – 8:00pm.
Sept 12th, 2014: Myelo Therapeutics has been selected to present at Falling Walls Venture on Nov 8th, 2014 in Berlin:
Falling Walls, the International Conference on Future Breakthroughs in Science and Society